Postoperative Giredestrant in Hormone-Positive Breast Cancer Draws Attention at SABCS 2025
In this article
Adjuvant Treatment in ER-Positive Early Breast Cancer: lidERA Findings at SABCS 2025
ER-positive (ER+), HER2-negative early breast cancer is the commonest subtype in clinical practice. Despite standard adjuvant endocrine therapy, recurrence risk is not eliminated. Can endocrine treatment be made more effective? Presented at SABCS 2025, lidERA is a study seeking a compelling answer with the oral SERD drug giredestrant .
1) What Is lidERA Testing?
Giredestrantis a next-generation estrogen receptor-targeting oral SERD candidate. In adjuvant endocrine treatment, the aim is to improve on standard options used for many years by further reducing invasive recurrence risk. lidERA is among the most important Phase 3 programs seeking to establish SERDs in the adjuvant setting. [1]
2) Study Design: Who Participated, and What Was Compared?
lidERA, Stage I–III, ER+/HER2−, intermediate–high-risk early breast cancer was studied in this Phase 3 trial. Patients were randomized 1:1 to:
• Giredestrant 30 mg (1 daily, orally) or
• Standard endocrine therapy (physician's choice of tamoxifen, anastrozole, letrozole or exemestane)
In the presented analysis, median follow-up was ~32 months . [2]
3) Primary Result: Was There an iDFS Difference?
Bars: iDFS at Month 36 (%)What Does HR 0.70 Mean?
In the giredestrant arm, the risk of invasive recurrence or deathwas reported as approximately 30% lower than with standard endocrine therapy: HR 0.70 (95% CI: 0.57–0.87; p=0.0014).
Simply, the likelihood of an adverse event over the same period was lower with giredestrant. Beyond statistical significance, this suggests a potentially clinically meaningful change in the adjuvant setting.
4) A Quick Numerical Summary
| Endpoint | Giredestrant | SOC ET | Interpretation |
|---|---|---|---|
| iDFS (primary) | HR 0.70 | — | ~30% relative risk reduction (p=0.0014) |
| Month 36 iDFS | 92.4% | 89.6% | The absolute difference looks small but matters at adjuvant scale |
| OS (interim analysis) | HR 0.79 | — | Immature data; not statistically significant |
| Subgroups | Consistent | — | Generally similar direction in prespecified subgroups |
Note: Figures come from press briefings/reported abstracts; full publications and longer reports will clarify subgroup details.
5) The Key Clinical Question: Who Needs It, and When?
lidERA strengthens the idea that ER+ early-stage treatment should do more than extend duration: it could suppress endocrine resistance from the outset . However, adjuvant decisions also account for risk level (nodal status, tumor burden, biology), menopausal status, concomitant treatments (chemotherapy/CDK4/6 inhibitors, etc.) and tolerability .
Side Effects: Any Unexpected New Toxicity?
Presented safety data indicate a profile broadly consistent with expected endocrine side effects, with no unexpected new safety signal reported.
The most frequently reported treatment-related events included:
• Arthralgia (joint pain)
• Hot flushes
• Headache .
Notably, according to the briefing, discontinuation rates with giredestrant could be lower than with standard endocrine treatment for certain adverse effects.
6 Frequently Asked Questions
DROZDOGAN Academy Commentary
Success in ER+ early disease depends on more than one intervention: accurate risk stratification + appropriate adjuvant intensity + long-term adherence. lidERA marks an important milestone suggesting that, in adjuvant endocrine therapy, a new class after 25 years (oral SERDs) could truly make a difference. The critical questions now are whether, with longer follow-up , the advantage persists and which biological subgroups derive the greatest value.
References
- Roche press release: “Giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer” (November 2025). ↩︎
- SABCS 2025 press briefing/abstract reports: lidERA iDFS HR 0.70 (95% CI 0.57–0.87; p=0.0014), Month 36 iDFS 92.4% vs 89.6%, interim OS HR 0.79 (not significant); common TEAEs: arthralgia/hot flushes/headache. ↩︎
Editor's note: Congress data may be expanded in later full publications; clinical decisions should consider current guidelines and licensing information.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.